Aromatase Inhibitors and Weight Loss in Severely Obese Men With Hypogonadism

PHASE4CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

April 15, 2018

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions
Hypogonadism, HypogonadotropicObesity
Interventions
DRUG

anastrozole (1 mg/day)

Participants will take Anastrozole 1mg per day, attend behavioral classes conducted by a dietitian, receive instruction on how to loss 10% of their body weight and participate in a supervised exercise training program.

DRUG

Placebo

Participants will take a placebo tablet every day, attend behavioral classes conducted by a dietitian, receive instruction on how to loss 10% of their body weight and participate in a supervised exercise training program.

Trial Locations (1)

77030

Michael E. DeBakey VAMC, Houston

All Listed Sponsors
lead

Baylor College of Medicine

OTHER

NCT03490513 - Aromatase Inhibitors and Weight Loss in Severely Obese Men With Hypogonadism | Biotech Hunter | Biotech Hunter